First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
New study presents a human-relevant stress model for assessing potential therapeutics
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Subscribe To Our Newsletter & Stay Updated
